**S7 Table: Sensitivity analyses in older Norwegian women (≥ 65 years). Never drinkers, non-drinkers last year, those with medical diagnoses at baselinea and those who died within the first year after participation in HUNT3 all excluded. Overall sample characteristics and according to mortality (N = 1,337). The HUNT Study 2006-08 (HUNT3)**

**Overall** **Alive** **Dead** **p-value**

Overall N (%) 1337 (100) 1245 (93.1) 92 (6.9)

Age Mean (SD) 72.5 (5.9) 72.1 (5.6) 78.3 (7.7)

Median (range) 71.1 (65-95.6) 70.8 (65.1-95.6) 78.9 (65.1-95.6) < 0.001b

Age category

65-74 years N (%)\* (%)\*\* 919 (68.7) (100) 886 (71.2) (96.4) 33 (35.9) (3.6) < 0.001c

≥ 75 years N (%)\* (%)\*\* 418 (31.3) (100) 359 (28.8) (85.9) 59 (64.1) (14.1)

Level of education1

Up to ten years education N (%)\* (%)\*\* 1002 (84.1) (100) 932 (84.0) (93.0) 70 (85.4) (7.0) 0.771d

Vocational and general N (%)\* (%)\*\* 24 (2.0) (100) 22 (2.0) (91.7) 2 (2.4) (8.3)

College and university N (%)\* (%)\*\* 165 (13.9) (100) 155 (14.0) (93.9) 10 (12.2) (6.1)

Residence1

Urban N (%)\* (%)\*\* 859 (64.9) (100) 803 (65.1) (93.5) 56 (61.5) (6.5) 0.489c

Rural N (%)\* (%)\*\* 465 (35.1) (100) 430 (34.9) (92.5) 35 (38.5) (7.5)

Marital status1

No living spouse or partner N (%)\* (%)\*\* 585 (43.8) (100) 530 (42.6) (90.6) 55 (59.8) (9.4) 0.001c

Living spouse or partner N (%)\* (%)\*\* 751 (56.2) (100) 714 (57.4) (95.1) 37 (40.2) (4.9)

Smoking status1

Never smoked N (%)\* (%)\*\* 664 (52.1) (100) 628 (52.8) (94.6) 36 (42.4) (5.4) 0.017c

Former smoker N (%)\* (%)\*\* 379 (29.7) (100) 355 (29.9) (93.7) 24 (28.2) (6.3)

Smoker N (%)\* (%)\*\* 231 (18.2) (100) 206 (17.3) (89.2) 25 (29.4) (10.8)

Overall health status1

Poor/not so good N (%)\* (%)\*\* 216 (16.8) (100) 187 (15.7) (86.6) 29 (32.2) (13.4) < 0.001c

Good/very good N (%)\* (%)\*\* 1067 (83.2) (100) 1006 (84.3) (94.3) 61 (67.8) (5.7)

HADS anxiety Mean (SD) 3.7 (2.9) 3.6 (2.9) 4.1 (3.4)

Median (range) 3 (0-15) 3 (0-15) 3 (0-15) 0.514b

HADS depression Mean (SD) 3.3 (2.6) 3.3 (2.6) 3.9 (2.9)

Median (range) 3 (0-15) 3 (0-15) 3 (0-12) 0.073b

**Overall** **Alive** **Dead** **p-value**

Drinking frequency2

Few times a year N (%)\* (%)\*\* 556 (41.6) (100) 518 (41.6) (93.2) 38 (41.3) (6.8) 0.513d

About once a month N (%)\* (%)\*\* 170 (12.7) (100) 152 (12.2) (89.4) 18 (19.6) (10.6)

2-3 days a month N (%)\* (%)\*\* 225 (16.9) (100) 211 (16.9) (93.8) 14 (15.2) (6.2)

1 day a week N (%)\* (%)\*\* 230 (17.2) (100) 216 (17.4) (93.9) 14 (15.2) (6.1)

2-3 days a week N (%)\* (%)\*\* 125 (9.3) (100) 118 (9.5) (94.4) 7 (7.6) (5.6)

4-7 days a week N (%)\* (%)\*\* 31 (2.3) (100) 30 (2.4) (96.7) 1 (1.1) (3.3)

Drugs with addiction potential3

BZD, z-hypnotics or opioids N (%)\* (%)\*\* 383 (28.6) (100) 348 (28.0) (90.9) 35 (38.0) (10.1) 0.039c

BZD or z-hypnotics N (%)\* (%)\*\* 334 (25.0) (100) 308 (24.7) (92.2) 26 (28.3) (7.8) 0.451c

BZD N (%)\* (%)\*\* 131 (9.8) (100) 122 (9.8) (93.2) 9 (9.8) (6.8) 0.996c

Z-hypnotics N (%)\* (%)\*\* 247 (18.5) (100) 226 (18.2) (91.5) 21 (22.8) (8.5) 0.265c

Opioids N (%)\* (%)\*\* 84 (6.3) (100) 67 (5.4) (79.8) 17 (18.5) (20.2) < 0.001c

Possible combination of alcohol

consumption ≥ 4 days/week2 and

use of prescribed drugs with addiction

potential3 N (%)\* (%)\*\* 9 (0.7) (100) 9 (0.7) (100) 0 (0.0) (0.0) 1.000d

HADS = Hospital Anxiety and Depression Scale; BZD = benzodiazepines

\*Column percent

\*\*Row percent

1Number do not sum up to 1,337 because of missing information.

2Self-reported alcohol consumption assessed among participants in HUNT3.

3Information about prescribed drugs with addiction potential among participants in HUNT3 (2006-08) was drawn from the Norwegian Prescription Database. Drugs with addiction potential were defined as at least one prescription of benzodiazepines, z-hypnotics or opioids in two consecutive years (2005/2006, 2006/2007, 2007/2008 or 2008/2009). Benzodiazepines defined by N03AE, N05BA and N05CD. Z-hypnotics defined by N05CF. Opioids defined by N02A.

aExcluded participants in HUNT3 with circulatory diseases, respiratory diseases, kidney disease, diabetes, cancer and musculoskeletal diseases at baseline.

bSignificance testing with Mann-Whitney U test betweenalive and dead participants (follow-up period from 2006 to 2013).

cSignificance testing with Chi-square test betweenalive and dead participants (follow-up period from 2006 to 2013).

dSignificance testing with Fisher’s Exact test between alive and dead participants (follow-up period from 2006 to 2013).